Dyadic International (DYAI): Customer Map and What It Means for Investors

Dyadic commercializes its proprietary microbial production platforms (notably the C1 platform) by licensing technology, delivering R&D services, and taking milestone, royalty and profit-share proceeds as partners commercialize animal‑free proteins and enzymes. Revenue flows are a mix of upfront license fees, milestone payments, research services and downstream profit shares, with near-term commercial revenue expected from partner manufacturing launches in albumin and food enzymes. For a concise investor briefing and relationship tracking, visit https://nullexposure.com/.

Why the customer roster matters — a short investor take

Dyadic operates as a hybrid licensor and service provider that monetizes intellectual property through long-duration license agreements and collaborative commercialization deals. The company’s customer base is concentrated, geographically diversified (U.S., EMEA and APAC exposure) and shows a pipeline that moves from funded R&D to near-term commercial revenue. Key investment drivers are partner execution on commercial launches and milestone realizations; primary risks are concentration and execution by third‑party manufacturers.

• Contracting posture: Licensing and collaborative arrangements are core; contracts include upfront fees, milestone triggers and royalty/profit‑share clauses.
• Concentration and criticality: Two customers historically generated a majority of revenue, which implies material dependency on a small set of partners.
• Maturity of relationships: A mix of early research deals and multi‑year commercialization partnerships — several programs are transitioning to commercial launch.

Explore how these relationship details affect valuations and risk profiles at https://nullexposure.com/.

Relationship roster — line by line

Below I cover every relationship cited in Dyadic’s customer results with a concise plain‑English summary and the source.

Inzymes (10‑K, FY2024)

Dyadic’s 2024 Form 10‑K reports that license revenue for the year ended December 31, 2024 was tied to the Inzymes and Proliant license agreements, signaling that Inzymes is a revenue-bearing license partner. According to Dyadic’s 2024 10‑K filing, Inzymes contributed to license revenue in FY2024.

Janssen (10‑K, FY2024)

The 2024 10‑K notes that license revenue in the prior year (ended 12/31/2023) was connected to the Janssen license agreement, indicating Janssen has been a historical license partner. Dyadic’s 2024 Form 10‑K references license revenue associated with the Janssen agreement for the 2023 period.

Proliant (10‑K, FY2024)

Dyadic discloses that Proliant’s license agreement was one of the sources of license revenue in FY2024; this confirms Proliant as a material license counterparty. The 2024 Form 10‑K lists Proliant among the agreements generating license revenue.

Fermbox Bio (earnings call, 2025 Q3)

Dyadic told investors on its 2025 Q3 earnings call that the collaboration with Fermbox Bio on an enzyme cocktail to convert agricultural residues into fermentable sugars is advancing and delivering results. Management described the Fermbox collaboration on the 2025 Q3 earnings call.

Proliant Health and Biologicals (GlobeNewswire, Sep 2024)

A GlobeNewswire release in September 2024 reported that Proliant Health and Biologicals paid Dyadic $1.0 million in Q3 and that future payments and a share of profits from recombinant albumin sales are expected as productivity goals are met. According to the GlobeNewswire announcement (Sep 2024), Dyadic received a Q3 payment and stands to share profits.

Opes Diagnostics Limited (GlobeNewswire, Dec 2025)

Dyadic announced a commercial agreement with Opes Diagnostics in December 2025 to support launch of recombinant human and bovine transferrin and FGF products for serum‑free media applications, indicating a commercial go‑to‑market partner for growth‑factor and media proteins. The GlobeNewswire release (Dec 2025) details the Opes commercial agreement.

Proliant Health & Biologicals (GlobeNewswire, Feb 2026)

A GlobeNewswire release in February 2026 confirms that under the commercial launch agreement Dyadic will receive a share of profits from Proliant’s commercial sales of recombinant human albumin. The Feb 2026 GlobeNewswire item states Dyadic’s profit‑share arrangement with Proliant for albumin.

Rabian BV (GlobeNewswire, Mar 2024 release referenced)

Dyadic reported that Rabian BV will use approximately €1.7 million to develop a rabies vaccine using Dyadic’s C1 platform, with Dyadic receiving an equity stake, funded R&D and milestones/royalties upon commercialization. The company highlighted this arrangement in a GlobeNewswire release discussing Rabian’s funded program.

Inzymes (GlobeNewswire, Aug 2025)

In mid‑2025 Dyadic flagged an expected $250,000 milestone payment from Inzymes for productivity achievements, indicating staged payments tied to development progress. The Aug 2025 financial‑results release (GlobeNewswire) noted the anticipated Inzymes milestone.

Proliant Health and Biologicals (GlobeNewswire, Aug 2025)

In its August 2025 progress report Dyadic reiterated that the Proliant partnership was advancing toward a 2025 commercial launch of animal‑free serum albumin for cell culture and diagnostics. The Aug 2025 release (GlobeNewswire) describes the expected Proliant launch timeline.

Fermbox Bio (GlobeNewswire, Aug 2025)

Dyadic reported that initial enzyme delivery to Fermbox Bio completed following a purchase order, marking execution of an initial commercial supply step. The Aug 2025 GlobeNewswire update references the completed initial delivery.

Inzymes ApS (GlobeNewswire, Mar 2026)

A March 2026 GlobeNewswire announcement says Dyadic and Inzymes ApS planned a 2026 commercialization of recombinant non‑animal bovine chymosin after final development milestones were achieved. The Mar 2026 release describes the planned commercialization of bovine chymosin.

Janssen Biotech, Inc. (GlobeNewswire release describing 2021 agreement)

Dyadic disclosed a 2021 research license and collaboration with Janssen in which Janssen paid a $500,000 upfront fee for non‑exclusive rights to develop C1 production cell lines for Janssen’s therapeutic protein candidates. The 2021 GlobeNewswire summary of that agreement notes the $500,000 upfront payment.

ProLiant Health and Biologics (earnings call, 2025 Q3)

On the 2025 Q3 earnings call, management said the recombinant human albumin program with ProLiant was advancing toward a commercial launch in early 2026. The 2025 Q3 earnings call cited ProLiant’s timeline toward commercialization.

What investors should prioritize next

• Monitor milestone receipts and profit‑share flows from Proliant and PHB as these are the most direct path to scalable revenue. Proven commercial sales will materially re‑rate revenue expectations.
• Track concentration risk: Dyadic reported two significant customers accounted for >50% of revenue, so partner disruptions would stress near‑term results.
• Watch geographic diversification: revenue outside the U.S. increased materially in 2024, which reduces single‑market exposure but adds cross‑border execution and regulatory complexity.
• Validate execution on launches (albumin, chymosin, growth factors) and confirm timing and commercialization economics disclosed by partners.

Bottom line: Dyadic’s business model is license‑and‑collaborate — revenue hinges on partner execution and milestone realization rather than direct large‑scale manufacturing today. For an ongoing monitor of partner milestones and customer risk, visit https://nullexposure.com/.

If you need a tailored investor memo or a relationship‑level risk heat map based on these disclosures, I can prepare that next. Review more Dyadic relationship intelligence and alerts at https://nullexposure.com/.